Boehringer Ingelheim Corporation

Type: Company

Name: Boehringer Ingelheim Corporation

First reported 19 hours ago - Updated 4 hours ago - 1 reports

FDA Food & Drug Administration

A Boehringer Ingelheim Corporation Shake Up and an FDA Warning Letter Over Production Gaffes

Staying up-to-date has never been simpler. Sign up for the today! After a string of grave and embarrassing manufacturing problems, Boehringer Ingelheim is overhauling some of its management. Late last week, Boehringer Ingelheim quietly posted on its web ... [Published BioSpace - 19 hours ago]

Entities: Boehringer Ingelheim Corporation, Warning Letter, FDA Food & Drug Administration, Boehringer Ingelheim GmbH, Spiriva HandiHaler

Quotes

...opellants," said Tunde Otulana, M D , Acting Head, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc. "COMBIVENT RESPIMAT is an example of Boehringer Ingelheim's commitment to providing unique products to help people living with respiratory conditions effectively manage their disease." The recommended dose for COMBIVENT RESPIMAT is one inhalation four times a day as compared to COMBIVENT MDI, which is administered as two inhalations...

Transition to Propellant-Free CombiventÂ® RespimatÂ® (ipratropium bromide and albuterol) Inhalati ... [Published TickerTech.com - May 17 2013]

...said Christophe Arbet-Engels, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The contributing role of persistently high glucose levels in the progression of type 2 diabetes has led to the need for a better understanding of how glucose is reabsorbed by the kidneys. The Boehringer Ingelheim and Lilly Diabetes alliance is very pleased to offer healthcare professionals an educational resource they can use at their convenience to gain greater knowledge of this process."

Boehringer Ingelheim, Lilly launch SGLT disease education initiative [Published PharmaBiz - May 04 2013]

...Sabine Luik, M D , senior vice president, medicine & regulatory affairs, U S regional medical director, Boehringer Ingelheim Pharmaceuticals, Inc. "We have worked closely with the FDA to reinforce the importance of adhering to PRADAXA to reduce the risk of stroke through this updated label. Patients should not stop taking PRADAXA unless directed by a physician."

Boehringer Ingelheim Corporation's Anticoagulant Pradaxa Adds Warning to Prescribing Info [Published BioSpace - Apr 30 2013]

"Several factors influence the likelihood of treatment success in HCV mono-infected patients, including personal genetic makeup, viral genotype and stage of liver disease. Co-infection with HIV contributes additional factors, including potential drug-drug interactions, that influence treatment decisions and outcomes" said lead study investigator Douglas Dieterich, MD, Professor of Medicine, Liver Diseases at Mount Sinai Medical Center, New York, NY...

Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co- ... [Published Yahoo! Finance - Mar 04 2013]

More Content

sort by: Date \| Relevance
A Boehringer Ingelheim Corporation Shake Up and... [Published BioSpace - 19 hours ago]
Transition to Propellant-Free CombiventÂ® Respi... [Published TickerTech.com - May 17 2013]
Boehringer Ingelheim, Lilly launch SGLT disease... [Published PharmaBiz - May 04 2013]
Boehringer Ingelheim Pharmaceuticals, Inc. and ... [Published Equities.com - May 02 2013]
Boehringer Ingelheim Corporation's Anticoagulan... [Published BioSpace - Apr 30 2013]
Boehringer Ingelheim Announces Interim Results ... [Published Yahoo! Finance - Mar 04 2013]
New Study Results Published in the New England ... [Published Yahoo! Finance - Feb 20 2013]
Boehringer Ingelheim recalls single manufacturi... [Published PharmaBiz - Nov 08 2012]
Boehringer Ingelheim RE-LY sub-analysis shows s... [Published PharmaBiz - Nov 06 2012]